The transcription factor, E2F, plays a critical role in the transactivation of several genes involved in cell cycle regulation. Previous studies showed that the transfection of cis element double-stranded decoy oligodeoxynucleotides (ODNs) corresponding to E2F binding sites inhibited the proliferation of vascular smooth muscle cells (VSMCs) and neointimal hyperplasia in injured vessels. We have developed a novel E2F decoy ODN with a circular dumbbell structure (CD-E2F) and compared its effects with those of the conventional phosphorothioated E2F decoy (PS-E2F) ODN. CD-E2F ODN was more stable than PS-E2F ODN, largely preserving its structural integrity after incubation in the presence of nucleases and sera. Moreover, CD-E2F ODN inhibited high glucose-and serum-induced transcriptional expression of cell cycle regulatory genes more strongly than PS-E2F ODN. Transfection of CD-E2F ODN resulted in more effective inhibition of VSMC proliferation in vitro and neointimal formation in vivo, compared with PS-E2F ODN. An approximately 40-50% lower dose of CD-E2F ODN than PS-E2F ODN was sufficient to attain similar effects. In conclusion, our results indicate that CD-E2F ODN may be a valuable tool in gene therapy protocols for inhibiting VSMC proliferation and studying transcriptional regulation.
Introduction
Double-stranded oligodeoxynucleotides (ODNs) ('decoy') that reduce the trans-activity of transcription factors are an innovative and attractive strategy for gene therapy and the functional study of gene products. Several different structures of doublestranded DNA, including unmodified oligonucleotide duplexes, ab-anomeric oligonucleotides, phosphorothioate oligonucleotide duplexes and dumbbell oligonucleotides, have been introduced as decoys for transcription factors. [1] [2] [3] [4] [5] [6] [7] [8] The main limitation of unmodified ODN is relatively easy degradation by nucleases prevalent in sera and cells. To rectify this problem, ODNs with modified linkages, such as phosphorothioate and methylphosphonate, were developed. However, these modified ODNs exhibited problems, such as insensitivity to RNase H, mutational potential by hydrolyzed modified nucleotides, lack of sequencespecific binding effects of ODN-based gene therapy and immune activation. [9] [10] [11] [12] On the other hand, circular dumbbell ODNs constructed by the enzymatic ligation of the 3 0 and the 5 0 ends of ODNs exhibit increased stability to exonucleases, easy uptake and a nontoxic unmodified backbone, which resembles natural DNA.
Neointimal hyperplasia and restenosis are the major problems limiting the long-term efficacy of percutaneous transluminal coronary angioplasty. [13] [14] [15] Common events in vascular response to arterial injury include proliferation and migration of vascular smooth muscle cells (VSMCs) within the arterial intimal and neointimal formation in injured vessels. Recent reports demonstrate that the transcription factor, E2F, which forms a complex with cyclin A, cdk2 and pRB, activates and phosphorylates these cell cycle regulatory genes and is critical in the process of cell growth and proliferation. [16] [17] [18] [19] [20] Moreover, administration of antisense or decoy ODN against c-myb, c-myc, cdc2, cdk2, NF-kB and E2F leads to a decrease in intimal thickening during experimental restenosis. [21] [22] [23] [24] [25] We have designed a novel E2F decoy ODN by the covalent closure of two identical ODN molecules to avoid exonuclease digestion. This study explores the stability and sequence-specific inhibition effects of this circular dumbbell E2F decoy (CD-E2F) ODN on transactivation of essential cell cycle regulatory genes, VSMC proliferation and neointimal formation.
Results

Stability of CD-E2F ODN
We initially examined the molecular stability of newly synthesized CD-E2F ODNs (Figure 1 ) in the presence of nucleases. As expected, CD-E2F ODN was resistant to exonuclease III and observed as a major band in gel electrophoresis. In contrast to CD-E2F ODN, both phosphorothioate linear E2F decoy (PS-E2F) ODN and annealed ODN prior to ligation of CD-E2F ODN were completely degraded after 2 h of incubation with exonuclease III. To confirm the stem loop structure of CD-E2F ODN, we further examined its molecular characteristics, using S1 nuclease. Decoy ODNs were incubated with S1 nuclease, which digests singlestranded regions in DNA molecules. The 74-base CD-E2F ODN stem region and 50-base PS-E2F ODN, but not annealed ODN, were protected from S1 nuclease digestion (Figure 2a) .
Exonuclease constitutes most of the nuclease activity in the cytoplasm and serum. We tested the stability of the decoy ODNs by incubation with sera that were not heatinactivated. Decoy ODNs were treated with 50% human, fetal bovine or calf serum for 24 h. Both PS-E2F and annealed ODN were significantly hydrolyzed after 24 h of incubation with each individual serum. However, CD-E2F ODN remained largely intact following incubation with the different sera, indicating greatly improved stability compared to both PS-E2F and annealed ODN ( Figure 2a) .
Next, we examined the stability of decoy ODNs in transfected cells in vitro and arteries in vivo (Figures 2b  and 2c ). In the case of fluorescein-labeled PS-E2F ODN, fluorescence decayed with a half-life of B3 days in cells and B5 days in the arterial wall. However, the half-life of fluorescein-labeled CD-E2F ODN was extended to B5.5 days in cells and B8 days in arteries, indicating a marked increase in stability.
Specific binding of E2F to CD-E2F ODN containing the E2F target site
To examine the sequence specificity of CD-E2F ODN, an in vitro competition assay was performed (Figure 3a ). An increase in the concentration of unlabeled E2F decoy ODN produced a corresponding decrease in the intensity of the retarded band, thus suggesting the presence of an ODN-E2F protein complex. A 1000-fold molar excess of non-labeled PS-E2F ODN employed as competitor successfully competed for E2F binding to labeled probe. Importantly, when CD-E2F ODN was used as a competitor instead of PS-E2F ODN, only a 100-fold molar excess of non-labeled ODN was required to completely compete for E2F binding to labeled probe. To characterize comprehensively the CD-E2F decoy ODN, we examined the effects of various concentrations of decoy (1 nM -5 mM) on the ability to inhibit E2F DNAbinding activity (Figure 3b ). Both CD-E2F and PS-E2F exhibited sequence-specific and dose-dependent activity. Inhibition by CD-E2F was observed at concentrations as low as 10 nM and was maximal (95%) at 300 nM ( Figure  3b , Po0.00001, compared to control). The dose-response curve for PS-E2F was shifted to the right, and an approximately five-fold higher concentration of decoy ODN was required to observe an effect (Po0.001, compared to CD-E2F). Decoy ODNs were added to cells with Lipofectin as a carrier molecule. Due to the observed toxicity of Lipofectin for cells at concentrations higher than 15 ml/ml culture (equivalent to 300 nM decoy ODN concentration), decoy ODN concentrations were limited to r100 nM in our initial experiments.
Next, we transfected decoy ODNs into cells to determine whether these ODNs specifically inhibit the high glucose-and serum-induced DNA-binding activity of E2F (Figure 3c ). As expected, culturing in conditioned media containing high glucose and serum significantly increased E2F binding activity, compared to control media (P o 0.01). Transfection of PS-E2F and CD-E2F ODN significantly attenuated E2F DNA-binding activity induced by high glucose and serum (P o 0.01). Notably, CD-E2F ODN inhibited this increased E2F DNA-binding activity more effectively than PS-E2F ODN (P o 0.05).
Effect of E2F decoy ODN on promoter activity in VSMCs
We employed reporter gene constructs containing an E2F binding site in the promoter region to investigate the effect of E2F decoy ODN on promoter activity. To assess the role of E2F binding in the up-regulation of cyclin A promoter activity by high glucose, we transfected a series of luciferase reporter gene plasmids containing various lengths of the human cyclin A 5' flanking sequence into VSMCs treated with high glucose concentrations (Figure 4a ). Only two plasmids (pCA-133/+205 and pCA-133/-2) displayed significantly decreased luciferase activity. The lowest activity was observed in pCA-133/ À2 constructs in which the two E2F binding sites from the cyclin A promoter were deleted. These data indicate that the E2F site mediates the up-regulation of cyclin A promoter activity in conditions of high glucose in VSMCs. Next, we investigated the inhibitory effect of E2F decoy ODN on the promoter activity of reporter gene plasmids, pCA-266/+205 and [E2F] Â 4-Luc, which contains four E2F binding sites in the promoter region (Figures 4b and 4c) . As expected, co-transfection of E2F decoy ODN markedly attenuated up-regulated luciferase gene expression by high glucose and serum in a dosedependent manner (Figures 4b and 4c , P o 0.01). CD-E2F ODN was more effective than PS-E2F ODN (P o 0.05), while the mutated circular dumbbell E2F decoy (M-E2F) 
Effects of E2F decoy ODN on the expression of cell cycle regulatory genes in VSMCs
We assessed the effects of E2F decoy ODN on the expression of endogenous cell cycle regulatory genes. As shown in Figure 5 , high glucose and serum stimulated the expression of cyclin A and PCNA genes in both human and rat VSMCs (P o 0.05). E2F decoy ODN, but not M-E2F ODN transfection resulted in the attenuation of gene expression of both PCNA and cyclin A in a dosedependent manner (P o 0.01). However, 18S rRNA expression was not affected by E2F decoy ODNs. The inhibitory effects of CD-E2F ODN on gene expression were greater than those of PS-E2F ODN in stimulatory conditions (P o 0.05).
Effects of E2F decoy ODN on the inhibition of VSMC growth in vitro
Since vascular responses to balloon injury commonly include the proliferation of VSMCs, E2F decoy ODNs were tested for their ability to inhibit smooth muscle cell growth (Figures 6a and 6b ). High glucose and serum stimulated the growth of cultured primary human and rat VSMCs, compared to control cultures (Po0.01). Transfection of E2F decoy ODNs resulted in significant inhibition of cell growth stimulated by high glucose or 
Effect of CD-E2F ODN on neointimal formation in balloon-injured rat carotid artery
We tested the transfection efficiency of E2F decoy ODN into rat carotid artery using the HVJ (hemagglutinating virus of Japan)-liposome method (Figures 7a and 7b ). Transfection of fluorescein-labeled E2F decoy ODN using this method resulted in a strong fluorescence (Figure 7b ), which was readily detected in all layers of the artery. As shown in Figure 7 , vessels transfected with M-E2F ODN exhibited neointimal formation at 2 weeks after transfection, similar to untreated vessels. In contrast, a single administration of either PS-E2F ODN or CD-E2F ODN resulted in significant reduction of neointimal formation in a dose-dependent manner (P o 0.001). Consistent with in vitro data, the inhibitory effect of CD-E2F ODN on neointimal formation was more potent than that of PS-E2F ODN (P o 0.05). Decoy ODN treatment did not alter the medial area. The observed reduction in neointimal formation was limited to transfected regions. The PCNA gene is E2F-dependent and translates into a nuclear protein whose appearance correlates with the proliferative state of the cell. We thus explored the effect of balloon injury on PCNA levels and whether treatment with E2F decoy ODN inhibited PCNA expression. As shown in Figure 8 , no PCNA-positive staining was observed in the control (uninjured arteries). Two weeks after injury, we noted a marked increase in PCNApositive cells in the neointimal region and regrowing endothelial cells. However, the number of PCNApositive cells in vessels transfected with E2F decoy ODN was much lower than that in untransfected vessels.
Discussion
Several studies demonstrate that inhibition of cell cycle regulatory genes successfully blocks VSMC proliferation and neointimal formation in injured vessels. [21] [22] [23] [24] [25] However, inhibition of a single cell cycle regulatory gene is insufficient to prevent these processes. This investigation focuses on the transcription factor, E2F, which is associated with up-regulated expression of various genes involved in G1/S cell cycle progression, including PCNA, c-myc, c-myb, cdc2 and cdk2. 18, [26] [27] Our data reveal that transfection of E2F decoy ODNs successfully blocks proliferation of VSMCs and neointimal hyperplasia in injured vessels, consistent with previous in vitro and in vivo analyses.
In the present study, we have devised a novel circular dumbbell decoy ODN to improve stability against nucleases. Previously, modification of ODN with phosphorothioate, methylphosphonate or other foreign materials was employed to augment stability against nuclease activity. 4, 5 Although the stability of ODN against nucleases was enhanced by these chemical modifications, other problems were encountered due to the introduction of foreign materials into the DNA sequence. [9] [10] [11] [12] Dumbbell-type ODN is reported to increase nuclease resistance and uptake into cells, compared to the chemically modified linear ODN.
28,29 Accordingly, we designed a novel circular dumbbell ODN containing two binding sites for E2F in a single decoy molecule without an open end, thus allowing the multiple targeting of a target promoter site or more than one promoter site. As expected, CD-E2F ODN was more stable than PS-E2F ODN in vitro as well as in vivo. The sequence specificity of CD-E2F ODN, assessed by an in vitro competitive binding assay, was nearly 10 times greater than that of PS-E2F ODN. Furthermore, the inhibitory effect of CD-E2F ODN on glucose-and seruminduced E2F-binding activity in VSMCs was dosedependent and more potent than that of PS-E2F ODN. These results collectively indicate that CD-E2F ODN exhibits enhanced stability and effective sequence-specific inhibition of E2F binding. 
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Poor cellular uptake and subsequent lysosomal degradation after endocytosis of delivered ODN by conventional liposome methods are the major obstacles in ODN therapy. 30, 31 To overcome these problems, we employed the HVJ-liposome technique to transfect E2F decoy ODN into the rat carotid artery. In this delivery system, exogenous molecules, such as plasmid DNA or ODN, are enveloped in a liposome comprising phospholipids and cholesterol. The liposome is fused to UV-inactivated HVJ to form an HVJ-liposome. Proteins fused to the surface of the HVJ envelope stimulate fusion of the liposome with the cell membrane and deposition of molecules into the cell. We recently reported that transfection of a fluorescein-labeled decoy ODN using the HVJliposome method into cultured human VSMCs was more effective in gene transfer than a conventional transfection method. 32 In accordance with this observation, transfection of fluorescein-labeled decoy ODN using the HVJ-liposome method in vivo resulted in strong fluorescence that was readily detected in all layers of the artery. 
Although hyperglycemia is suggested to contribute to the development of macrovascular complications in patients with diabetes, few studies have focused on the direct effect of elevated glucose concentrations on VSMCs. [32] [33] [34] We examined the effect of high glucose on E2F DNA-binding activity in VSMCs and cell cycle regulatory genes, and proliferation of VSMCs. Our data show that E2F DNA-binding activity and luciferase activity of the [E2F] Â 4-luciferase construct were significantly increased after treatment with high concentrations of glucose in VSMCs. These effects were additive with serum. Moreover, high glucose and serum stimulated the endogenous expression of cell cycle regulatory genes, such as cyclin A and PCNA, which are important for cell cycle progression from G1 to the S phase. Transfection of E2F decoy ODN, but not M-E2F ODN, effectively attenuated VSMC proliferation and expression of PCNA and cyclin A genes induced by high glucose and serum in a dose-dependent manner, consistent with results of a promoter study on cyclin A. Furthermore, data from cyclin A promoter serial deletion or mutation constructs revealed that the glucose-stimulated up-regulation of cyclin A gene expression was mediated by the E2F site in the cyclin A promoter. Cotransfection of E2F decoy ODN (but not M-E2F ODN) with luciferase reporter constructs also completely abolished luciferase expression of cyclin A induced by high glucose.
Finally, transfection of CD-E2F ODN prevented neointimal formation after balloon injury more effectively than PS-E2F ODN. The number of cells positive for PCNA staining in vessels transfected with CD-E2F ODN was also much lower than that in vessels transfected with PS-E2F ODN or untransfected vessels. These observations, together with the in vitro results, suggest that CD-E2F ODN is more effective in suppressing VSMC growth and preventing neointimal formation, following vascular injury. An additional potential therapeutic benefit of CD-E2F ODN is its non-mutational potential, in contrast to modified ODN with foreign materials, which may display mutational potential when hydrolyzed nucleotides are introduced into genomic DNA during replication.
In conclusion, the present study demonstrates that CD-E2F ODN displays markedly enhanced stability and effective sequence-specific decoy effects, compared to previously modified ODNs. Moreover, inhibition of DNA-binding activity of E2F using CD-E2F ODN significantly decreased cell cycle regulatory gene expression and cell proliferation, both in vitro and in vivo. This method employing CD-E2F ODN and a highly effective HVJ-liposome delivery technique is a novel therapeutic 
Materials and methods
Animals
Male Sprague-Dawley (SD) rats aged 9-10 weeks and weighing 280-320 g were used. All procedures were compliant with the institutional guidelines for animal research.
Cell culture
Human VSMCs were isolated from the thoracic aorta of heart transplantation donors. Tissue collection was approved by the Ethics Committee of the institution. Rat VSMCs were harvested from the thoracic aorta of adult male SD rats. VSMCs were cultured in DMEM (Gibco BRL, Grand Island, NY, USA) containing 20% FBS (Gibco BRL). VSMC purity was determined by positive staining with smooth-muscle-specific a-actin monoclonal antibodies (Sigma, St Louis, MI, USA).
After attaining 80-90% confluence in 100 mm dishes, human VSMCs were serum-starved for 24 h in serumfree medium, and subjected to either control normal glucose (DMEM containing 5.5 mM D-glucose) or conditioned medium (DMEM containing 10% serum and 22 mM D-glucose). Cells were subsequently processed for nuclear protein or RNA extraction, as described below.
Construction of the 'dumbbell-type' decoy ODN
The sequences of dumbbell-type and phosphorothioated double-stranded ODN against the E2F binding site, and mutated ODNs are as follows: CD-E2F ODN (note: consensus sequences are underlined), 5
0 . CD-E2F ODN was predicted to form a stem-loop structure. The stem is formed by complementary sequences at both ends of each oligonucleotide. The 5 0 terminus of the stem contains six bases of a single-stranded sequence (5 0 -GGATCC-3 0 ) representing the restriction site for BamHI. Two oligonucleotide molecules were annealed at the complementary 6-base sequence of both 5' ends. ODNs were ligated for 2 h at a temperature range of 80-251C. Following the addition of T4 DNA ligase (1 unit), the mixture was incubated for 24 h at 161C to generate a covalently ligated dumbbell-type decoy molecule. CD-E2F ODN comprises two loops and one stem containing two E2F consensus sequences.
Stability test of CD-E2F ODN
To examine the stability of CD-E2F ODN, 1 mg PS-E2F ODN, non-ligated phosphodiester oligonucleotides and CD-E2F ODN were incubated with human serum, FBS, exonuclease III or S1 nuclease. All sera were used without heat inactivation to preserve DNase activity. Each serum was diluted by 50% when added to ODN in a 100 ml reaction volume, and mixtures were incubated for 24 h at 371C. Exonuclease III (Takara, Otsu, Japan) at 160 units/mg oligodeoxynucleotide was added to ODNs and incubated for 2 h at 371C. After the addition of S1 nuclease (Takara) at 10 units/mg oligodeoxynucleotide, ODNs were incubated for 30 min at 251C. The oligodeoxynucleotides were extracted with phenol and chloroform and examined on a 15% denaturing polyacrylamide gel.
We additionally compared the stability of transfected PS-E2F and CD-E2F in cells in vitro and arteries in vivo. PS-E2F and CD-E2F ODN were labeled with the Label IT s fluorescein nucleic acid labeling kit (Takara). At the indicated time points, transfected cells or arteries were homogenized in 1 ml PBS buffer, centrifuged and 400 ml supernatant was used for the measurement of fluorescence in a spectrofluorometer (RF5301PC spectrofluorophotometer, Shimadzu, Japan) (excitation: 490 nm; emission: 520 nm).
In vitro gene transfer
Cells were fed with fresh culture medium the day before decoy was added and washed twice with Opti-MEM (Gibco BRL), prior to the experiment. Cells were transfected with various concentrations of decoy ODN (1, 10, 100 and 300 nM) combined with Lipofectin 
Effect of decoy ODN on VSMC growth
VSMCs were seeded onto 96-well tissue culture plates. At 30% confluence, SMCs were rendered quiescent by incubation for 24 h in defined serumfree medium. Lipofectin:decoy ODN (containing 1, 10 and 100 nM of decoy ODN) was added to the wells, and cells were incubated at 371C for a further 5 h. After 2-3 days, an index of cell proliferation was determined with a WST cell counting kit (Wako, Osaka, Japan).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from VSMCs, as described previously. 32 In brief, DNA probes, such as those for E2F and mutated ODN, were labeled using [g-32 P]ATP and T4 polynucleotide kinase. Following end-labeling, 32 P-labeled ODNs were purified using a NAP-5 column. Protein-DNA binding reactions were performed at room temperature for 20 min in a volume of 20 ml. Reaction mixtures contained 6 mg nuclear extract, 100 mg/ml poly dI:dC, 10 mM Tris/HCl (pH 7.5), 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, 1 mM MgCl 2 , 4% glycerol and 60 000 cpm 32 P-labeled primer DNA. After incubation, samples were loaded onto 4% native polyacrylamide gels in 0.5 Â Tris-borate-EDTA buffer and run at 150 V for 2 h. Gels were dried and visualized by autoradiography. Experimental conditions for competition studies were identical, except that appropriate competitor ODNs were added to the reac- Novel E2F decoy oligodeoxynucleotides JD Ahn et al tion mixtures in 50-to 100-fold molar excess before adding nuclear extracts.
Luciferase assay
A series of luciferase reporter gene plasmids containing various lengths of human cyclin A 5' flanking sequence and E2F luciferase constructs were used to investigate the effects of E2F decoy ODN on promoter activity. To analyze luciferase expression, cells were washed twice with PBS and lysed with 200 ml of 1 x Reporter lysis buffer (Promega, Madison, WI, USA). Each lysate (50 ml) was examined for luciferase activity.
Northern blot analyses
Gene expression of PCNA and cyclin A was measured by Northern blotting. Total RNA (10 mg) was applied to 1% formaldehyde-agarose gel and transferred to a nylon membrane. Transferred RNA was hybridized to a radiolabeled PCNA or cyclin A cDNA probe in Express Hyb TM solution at 651C for 2 h, and membranes were washed according to the manufacturer's instructions. The membranes were exposed to X-ray film for 24-48 h, and mRNA expression was quantified by densitometric analyses. Loading differences were normalized using an 18S rRNA cDNA probe.
Preparation of HVJ-liposome
HVJ-liposomes were prepared as described previously. 32 Briefly, cholesterol, dioleoylphosphatidylethanolamine, phosphatidylcholine, sphingomyeline and phosphatidylserine were mixed in a molar ratio of 50:13. KCl, 10 mM Tris-HCl, pH 7.6) containing ODN. Liposomes were prepared by shaking and filtration. Purified HVJ (Z strain) was inactivated by UV irradiation for 3 min immediately before use. The liposome suspension was mixed with HVJ in a total volume of 2 ml BSS. The mixture was incubated at 41C for 5 min, followed by 30 min incubation with gentle shaking at 371C. Free HVJ was removed from HVJ-liposomes by sucrose density gradient centrifugation. The top layer of the sucrose gradient was collected for use.
Balloon injury and in vivo gene transfer
A 2 French Fogarty catheter was used to induce vascular injury in male SD rats. Rats were anesthetized with pentobarbital, and the left common carotid artery was surgically exposed. A cannula was introduced into the common carotid via the external carotid artery. In vivo gene transfer was performed after inducing vascular injury of the common carotid artery by inflating the balloon catheter three times. The injured segment was transiently isolated using temporary ligatures. After balloon injury, 20 ml HVJ-liposome complex containing CD-E2F, M-E2F, fluorescein-labeled PS-E2F ODN or HVJ-liposomes only was incubated within the lumen for 10 min at room temperature. Next, the infusion cannula was removed. Following transfection, blood flow to the common carotid artery was restored with ligature release, and the wound was closed. No adverse neurological or vascular effects were observed in any of the animals subjected to this procedure.
Histological analyses
Two weeks after transfection, rats were killed and vessels were perfusion-fixed with 4% paraformaldehyde. Neointimal size was quantified by morphometry of individuals blinded to sample identity. Intimal and medial areas were measured with a digitizing system (model INTUOS 6 Â 8, Wacom, Vancouver, WA, USA). In fluoresceinlabeled E2F decoy ODN transfections, vessels were harvested at indicated days following transfection and perfusion-fixed with 4% paraformaldehyde. Sections were examined by fluorescence microscopy. For immunohistochemisty, sections were incubated with rabbit anti-proliferating cell nuclear antigen antibody (1:200 dilution, SantaCruz, Santa Cruz, CA, USA) and processed using standard protocols.
Statistical analyses
Results are expressed as mean 7 s.e.m. Analysis of variance was performed with Duncan's test and used to determine significant differences in multiple comparisons. Values of P o 0.05 were taken as statistically significant. All experiments were performed at least three times.
